ArticleIJU case reports2026
Definitive Histologic Diagnosis of Bone Marrow Carcinomatosis Followed by Dose-Adjusted Chemotherapy in Metastatic Urothelial Carcinoma: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone marrow carcinomatosis (BMC) is a rare manifestation of metastatic urothelial carcinoma (UC) that may mimic hematologic disease and cause severe cytopenia, diagnostic difficulty, and rapid clinical deterioration. Case Presentation: A 65-year-old man presented with back pain, thrombocytopenia, and leukoerythroblastosis. Bone marrow aspiration resulted in a dry tap, but biopsy revealed diffuse carcinoma-cell infiltration consistent with UC, establishing BMC as the cause of marrow failure. Because of profound marrow dysfunction, reduced-dose gemcitabine and cisplatin chemotherapy was initiated, leading to hematologic recovery and radiologic improvement. The patient subsequently received standard-dose chemotherapy and avelumab maintenance and survived for 12.4 months after diagnosis. Conclusion: Histologic confirmation is essential to distinguish UC-related BMC from primary hematologic disease and may support individualized systemic treatment in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.